Stock Update (NYSE:MRK): Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: …

[Business Wire] – Merck , known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA® across a broad range of advanced cancers will . . . → Read More: Stock Update (NYSE:MRK): Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: … Similar Articles: Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Present New Data at the European Cancer Congress 2015 Reinforcing the Company’s Patient-Centric Focus Company Update: Merck & Co Inc (NYSE:MRK) – 2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented Company Update: Merck & Co Inc (NYSE:MRK) – Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.